THE CLINICAL AND ECONOMIC BURDEN OF CARDIOVASCULAR DISEASE ON 90-DAY UNPLANNED READMISSIONS IN PATIENTS WITH PROSTATE CANCER: AN ANALYSIS OF THE NATIONAL READMISSION DATABASE
Author(s)
HYUNJI KIM, PhD Student1, Chanhyun Park, MEd, RPh, PhD2, Sun-Kyeong Park, PhD1.
1The Catholic University of Korea, Bucheon, Korea, Republic of, 2The University of Texas at Austin, Austin, TX, USA.
1The Catholic University of Korea, Bucheon, Korea, Republic of, 2The University of Texas at Austin, Austin, TX, USA.
OBJECTIVES: Unplanned hospital readmissions are associated with substantial healthcare burden and adverse clinical outcomes. While prostate cancer patients often transition into long-term survivorship, cardiovascular disease (CVD) remains a leading cause of morbidity. However, the association between CVD and outcomes during unplanned readmission in this population remains poorly characterized. This study evaluated the association between CVD and in-hospital mortality, length of stay (LOS), and hospitalization costs during the first unplanned 90-day readmission in a nationally representative U.S. population.
METHODS: This retrospective cohort study utilized the 2017-2020 Nationwide Readmissions Database. Adult patients with prostate cancer who experienced a first unplanned readmission within 90 days were included. Baseline characteristics at index admission were balanced between patients with and without CVD using propensity score matching (PSM). Readmission outcomes were assessed using multivariable regression models, including in-hospital mortality, LOS, total costs and daily costs.
RESULTS: Among 210,902 hospitalizations of patients with prostate cancer, 24,694 first unplanned readmissions were identified; 19,202 were included after PSM. Compared to patients without CVD, those with CVD had significantly higher in-hospital mortality (10.23% vs. 7.06%; adjusted OR 1.26, 95% CI 1.12-1.42), higher total costs ($18,487 vs. $16,298; adjusted ratio 1.10, 95% CI 1.07-1.13), and higher daily costs (adjusted ratio 1.09, 95% CI 1.06-1.11). Notably, there was no significant difference in LOS between the two groups (adjusted ratio 1.01, 95% CI 0.99-1.04).
CONCLUSIONS: Among patients with prostate cancer, CVD was associated with significantly increased mortality and healthcare costs during unplanned 90-day readmissions. The higher economic burden despite a similar LOS suggests intensified resource utilization during these admissions. These results underscore the need for further studies to develop and evaluate targeted management strategies, such as coordinated cardio-oncology care, to reduce the clinical and economic burden of readmissions in this population.
METHODS: This retrospective cohort study utilized the 2017-2020 Nationwide Readmissions Database. Adult patients with prostate cancer who experienced a first unplanned readmission within 90 days were included. Baseline characteristics at index admission were balanced between patients with and without CVD using propensity score matching (PSM). Readmission outcomes were assessed using multivariable regression models, including in-hospital mortality, LOS, total costs and daily costs.
RESULTS: Among 210,902 hospitalizations of patients with prostate cancer, 24,694 first unplanned readmissions were identified; 19,202 were included after PSM. Compared to patients without CVD, those with CVD had significantly higher in-hospital mortality (10.23% vs. 7.06%; adjusted OR 1.26, 95% CI 1.12-1.42), higher total costs ($18,487 vs. $16,298; adjusted ratio 1.10, 95% CI 1.07-1.13), and higher daily costs (adjusted ratio 1.09, 95% CI 1.06-1.11). Notably, there was no significant difference in LOS between the two groups (adjusted ratio 1.01, 95% CI 0.99-1.04).
CONCLUSIONS: Among patients with prostate cancer, CVD was associated with significantly increased mortality and healthcare costs during unplanned 90-day readmissions. The higher economic burden despite a similar LOS suggests intensified resource utilization during these admissions. These results underscore the need for further studies to develop and evaluate targeted management strategies, such as coordinated cardio-oncology care, to reduce the clinical and economic burden of readmissions in this population.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
CO160
Topic
Clinical Outcomes, Epidemiology & Public Health, Real World Data & Information Systems
Topic Subcategory
Comparative Effectiveness or Efficacy
Disease
Cardiovascular Disorders (including MI, Stroke, Circulatory), Geriatrics, No Additional Disease & Conditions/Specialized Treatment Areas, Oncology, Urinary/Kidney Disorders